secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q32 Bio Inc. (QTTB)
CIK:        0001661998
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093295
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q32 Bio reports Q2 net loss of $17.0M; bempikibart AD trial enrollment completed at 121 patients
--------------------------------------------------------------------------------

- Net loss $17.0M ($1.42/share) vs $5.8M ($16.69) in Q2 2023; R&D expense rose to $13.4M from $8.0M.
- Cash and investments $107.6M as of June 30; expected funding into mid-2026.
- Completed enrollment in bempikibart AD Phase 2 trial (121 patients); topline results on track for Q4 2024.
- ADX-097 Phase 2 basket trial for renal diseases enrolling; initial open-label data expected by year-end 2024.
- Bempikibart AA Phase 2 topline results also expected in Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661998/000095017024093295/0000950170-24-093295-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661998/000095017024093295/qttb-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093295

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer